Sihuan Pharmaceutical Holdings Group Ltd.

SZSC:460 Stock Report

Market Cap: HK$6.1b

Sihuan Pharmaceutical Holdings Group Past Earnings Performance

Past criteria checks 0/6

Sihuan Pharmaceutical Holdings Group has been growing earnings at an average annual rate of 13%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been declining at an average rate of 9.9% per year.

Key information

13.0%

Earnings growth rate

12.6%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate-9.9%
Return on equity-4.1%
Net Margin-2.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sihuan Pharmaceutical Holdings Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSC:460 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,755-38940479
31 Mar 241,808-46926528
31 Dec 231,861-54911578
30 Jun 231,773-2,041898773
31 Mar 231,977-1,996961855
31 Dec 222,181-1,9511,023937
30 Jun 222,595-1441,139992
31 Mar 222,8171411,134930
31 Dec 213,0384271,129868
30 Sep 213,3046811,102815
30 Jun 213,3179451,049762
31 Mar 212,891727954746
31 Dec 202,464508859729
30 Sep 202,370-14792698
30 Jun 202,275-537725666
31 Mar 202,577-1,623721633
31 Dec 192,878-2,709717599
30 Sep 193,088-1,927722566
30 Jun 193,297-1,144727534
31 Mar 193,107238697507
31 Dec 182,9171,620667480
30 Sep 182,7511,496580482
30 Jun 182,5841,372494484
31 Mar 182,6651,411523394
31 Dec 172,7461,449553304
30 Sep 172,9921,632653152
30 Jun 173,2381,8157540
31 Mar 173,2121,7617200
31 Dec 163,1861,7086860
30 Sep 162,9841,5286270
30 Jun 162,7811,3475680
31 Mar 162,9741,7055900
31 Dec 153,1672,0626110
30 Sep 153,3212,1816480
30 Jun 153,4742,2996850
31 Mar 153,2791,9856580
31 Dec 143,0841,6716300
30 Sep 142,3651,58100
30 Jun 141,6451,491-6310
31 Mar 142,1161,388-830
31 Dec 132,5861,2854660

Quality Earnings: 460 is currently unprofitable.

Growing Profit Margin: 460 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 460 is unprofitable, but has reduced losses over the past 5 years at a rate of 13% per year.

Accelerating Growth: Unable to compare 460's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 460 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).

Return on Equity

High ROE: 460 has a negative Return on Equity (-4.06%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 18:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shaojing TongBofA Global Research
Harry HeChina Galaxy International Securities (Hong Kong)
Sze Chuen TamCore Pacific -Yamaichi International (H.K.) Limited